What the agency says to do
FDA’s record gives no instruction for consumers.
Note from Recalls Watch, not agency text
- Talk to your pharmacist or doctor before you stop taking a medicine. FDA: Medication Guides and your medicines (opens in a new tab)
- In an emergency call 911. For a possible poisoning call Poison Help at 1-800-222-1222. Poison Help (HRSA) (opens in a new tab)
- For refunds, repairs or replacements, follow the agency notice. Recalls.gov (opens in a new tab)
Why it was recalled
Presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel
The recalled product
Codes in the record. Click one to copy it.
FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terepht
Company announcement, as FDA publishes it
FOR IMMEDIATE RELEASE - ROCHESTER, MI– October 13, 2026 – Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel, that was detected in certain lots.
Administration of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) found to contain particulate matter, has a reasonable probability of causing life-threatening adverse health consequences including pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or inflammation of the walls of veins, which may lead to clotting. To date, Par Health has not received any reports of adverse events related to this recall.
Argatroban Injection 250 mg/2.5 mL (100 mg/mL) is a direct thrombin inhibitor indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) and as an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention.
Recalled product can be identified as follows and by representative labels at bottom of this document:
These lots were distributed nationwide to wholesalers and hospitals between December 30, 2024, and May 5, 2026.
Par Health is providing written notification to wholesale and hospital accounts that have received the affected lots and is arranging for return of all existing inventory through Inmar, Inc. Wholesale distributors and hospital pharmacies that have the product being recalled should immediately discontinue use and stop distribution. If you have further distributed the recalled product, please notify your accounts or any additional locations which may have received the recalled product.
Questions regarding this recall can be directed to Inmar, Inc. at 1-855-648-7909 Monday through Friday between the hours of 9 a.m. and 5 p.m. ET or by email at rxrecalls@inmar.com .
For medical or technical product information or to report a product complaint or adverse event please call 1-800-828-9393 Monday through Thursday between the hours of 9 a.m. and 8 p.m. ET or Friday between 9 a.m. and 6 p.m. ET.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Complete and submit the report Online : www.fda.gov/medwatch/report.htm
Regular Mail or Fax : Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Package Identification: See representative examples of vial labels from selected affected lots below:
Contacts Gena Holthaus, Senior Director, Corporate Brand and Communications media.relations@parhealth.com
*Par Pharmaceutical, Inc. and Endo USA, Inc. are predecessor companies to Par Health USA, LLC, the current distributor of the product.
Argatroban Injection 250 mg/2.5 mL (100 mg/mL), Distributed by: Par Pharmaceutical* or Endo USA*
- Lot or code
- NDC: 42023-182-01; Lot: 83449; Expiration Date: 10/2026
82682
- Lot or code
- NDC: 11/2026
86714
- Lot or code
- NDC: 02/2027
87302
- Lot or code
- NDC: 02/2027
87560
- Lot or code
- NDC: 02/2027
87753
- Lot or code
- NDC: 03/2027
88401
- Lot or code
- NDC: 03/2027
88614
- Lot or code
- NDC: 04/2027
88836
- Lot or code
- NDC: 04/2027
90220
- Lot or code
- NDC: 05/2027
91216
- Lot or code
- NDC: 06/2027
91219
- Lot or code
- NDC: 06/2027
92004
- Lot or code
- NDC: 07/2027
92006
- Lot or code
- NDC: 07/2027
92009
- Lot or code
- NDC: 08/2027
92596
- Lot or code
- NDC: 08/2027
92782
- Lot or code
- NDC: 08/2027
93107
- Lot or code
- NDC: 08/2027
93329
- Lot or code
- NDC: 08/2027
93890
- Lot or code
- NDC: 09/2027
42023-182-89
- Lot or code
- NDC: 84193; Lot: 10/2026
92880
- Lot or code
- NDC: 08/2027
Source
- Issued by
- U.S. Food and Drug Administration
- Firm
- Par Health USA, LLC (other notices of this firm)